Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Bello

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Medicina Clinica|September 11, 1998
[Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma]M Pérez Encinas, J L Bello, A Bendaña, et al.
Hepato-Gastroenterology|March 24, 2005
Prolonged survival after liver transplantation for Hodgkin's disease-induced fulminant liver failureI Abdulkader, M Fraga, A González-Quintela, et al.
Revista Clinica Espanola|March 1, 1985
[Chronic T lymphocytosis and neutropenia]J L Bello López, M J Gómez Vázquez, A Viejo Llorente, et al.
Sangre|April 1, 1997
[Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea]E Ojeda Gutiérrez, R Arrieta Gallastegui, J G Bustos, et al.
Leukemia|October 1, 1996
Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemiaC Richard, I Romón, M Perez-Encinas, et al.
Medical Mycology|June 21, 2012
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)I Jarque, M Tormo, J L Bello, et al.
Annals of Hematology|March 31, 2016
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trialE González-Barca, M Canales, A Salar, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?J F San Miguel, J J Lahuerta, R García-Sanz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Medicina Clinica|September 11, 1998
[Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma]M Pérez Encinas, J L Bello, A Bendaña, et al.
Hepato-Gastroenterology|March 24, 2005
Prolonged survival after liver transplantation for Hodgkin's disease-induced fulminant liver failureI Abdulkader, M Fraga, A González-Quintela, et al.
Revista Clinica Espanola|March 1, 1985
[Chronic T lymphocytosis and neutropenia]J L Bello López, M J Gómez Vázquez, A Viejo Llorente, et al.
Sangre|April 1, 1997
[Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea]E Ojeda Gutiérrez, R Arrieta Gallastegui, J G Bustos, et al.
Leukemia|October 1, 1996
Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemiaC Richard, I Romón, M Perez-Encinas, et al.
Medical Mycology|June 21, 2012
Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study)I Jarque, M Tormo, J L Bello, et al.
Annals of Hematology|March 31, 2016
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trialE González-Barca, M Canales, A Salar, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?J F San Miguel, J J Lahuerta, R García-Sanz, et al.
Pageof 3